
Preventing Myeloma Progression with Diet: The Nutrivention-2 Study
What is within a patient's control to slow or stop progression from MGUS or smoldering myeloma to active myeloma? And which supplements have any impact at all on our precursor condition or myeloma health?
Urvi Shah, MD of Memorial Sloan Kettering Cancer Center is running a series of studies called the NUTRIVENTION series to aggregate sufficient data to answer these critical questions. The first NUTRIVENTION study was an extensive, multi-month study that showed that a whole foods plant-based diet could actually slow disease progression.
Because Dr. Shah knows that the microbiome (or your gut health) has an impact on inflammation (which influences disease progression), she is now running the second study called NUTRIVENTION-2 study to identify the impact a whole foods plant based diet or supplements have on the microbiome. HealthTree is supporting Dr. Shah's study with study support as well as direct funding.
The study invites MGUS or smoldering myeloma patients (who are not on active treatment) to join the study for a 2-week intervention with one group implementing a 2-week whole foods plant-based diet, or the other three groups receiving one of three different types of supplements. Four in-home stool samples will be collected during the study to identify if the diet or an individual supplement improves microbiome health. Participation is virtual and no travel is necessary.
We invite you to join this study if you are an MGUS or smoldering myeloma patient today!
In this show, Dr. Shah shares her findings about the impact on diet, describes the NUTRIVENTION-2 study for MGUS and SMM patients, shares an upcoming study for newly diagnosed myeloma patients and also reveals her 5 top tips to more easily move towards a whole foods plant based diet.

Jenny Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Urvi Shah, MD
Dr. Urvi Shah is a faculty on the myeloma service, division of hematologic malignancies at Memorial Sloan Kettering Cancer Center. Her research focuses on studying the role of diet, microbiome, and other lifestyle-related risk factors in plasma cell disorders as well as identifying interventions to improve outcomes for these patients. She also studies immune therapies (including CAR T cell therapies) for myeloma. Being a lymphoma survivor herself she is passionate about helping patients make wise nutritional and lifestyle choices as they face a plasma cell disorder diagnosis as well as raising awareness about healthy choices to prevent cancer.
